1900 studies found for:    egfr
Show Display Options
Rank Status Study
1 Active, not recruiting Asia Pacific and Russia Diagnostic Study for EGFR Testing
Condition: EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.
Intervention: Genetic: EGFR mutation test
2 Recruiting Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)
Condition: Advanced EGFR-positive Solid Tumors
Intervention: Biological: CART-EGFR
3 Unknown  Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment
Condition: NSCLC
Intervention: Other: cancer cell lines establishment
4 Not yet recruiting EGFR Inhibitor AZD9291 and Necitumumab in Treating Patients With EGFR-Positive Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
Conditions: EGFR Activating Mutation;   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: EGFR Inhibitor AZD9291;   Other: Laboratory Biomarker Analysis;   Biological: Necitumumab;   Other: Pharmacological Study
5 Recruiting Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma
Condition: Carcinoma, Squamous Cell
Intervention: Biological: EGFR Antisense DNA
6 Recruiting CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR
Condition: Advanced Glioma
Intervention: Biological: anti-EGFR CAR T
7 Completed Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)
Condition: NSCLC Non Small Cells Lung Cancer
Intervention:
8 Not yet recruiting TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: EGFR Inhibitor AZD9291;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: TORC1/2 Inhibitor INK128
9 Completed Anti-EGFR Immunoliposomes in Solid Tumors
Condition: Solid Tumors
Intervention: Drug: anti-EGFR immunoliposomes loaded with doxorubicin
10 Recruiting Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)
Conditions: Non-Small Cell Lung Cancer;   Brain Metastases;   EGFR Gene Mutation
Interventions: Drug: Gefitinib;   Radiation: WBRT
11 Completed Laryngeal and Esophageal EGF-r Expression in Patients With Reflux Laryngitis
Conditions: Gastroesophageal Reflux Disease;   Chronic Laryngitis
Interventions: Procedure: Biopsy of the retrocrycoid laryngeal mucosa;   Procedure: Biopsy of the distal esophageal mucosa
12 Not yet recruiting Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC
Condition: Asymptomatic Brain Metastases of Non Small Cell Lung Cancer
Intervention: Drug: EGFR-TKI
13 Unknown  Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
Condition: EGFR Mutation Positive Non-small Cell Lung Cancer
Intervention: Drug: EGFR TKIs (gefitinib, erlotinib, afatinib, et al)
14 Completed Europe-Japan Diagnostic Study for EGFR Testing
Condition: EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.
Intervention:
15 Terminated A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors
Condition: EGFR Positive Solid Tumors
Intervention: Drug: IMGN289
16 Not yet recruiting EGFR Inhibitor AZD9291 and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: EGFR Inhibitor AZD9291;   Other: Laboratory Biomarker Analysis;   Biological: Navitoclax;   Other: Pharmacological Study
17 Active, not recruiting Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma
Conditions: Squamous Cell Carcinoma;   Head and Neck Cancer
Intervention: Biological: EGFR Antisense DNA
18 Completed Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas
Condition: Non-small Cell Lung Cancer Metastatic
Intervention: Biological: CTC
19 Recruiting Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC
Condition: Non Small Cell Lung Cancer
Interventions: Drug: EGFR-TKIs;   Radiation: thoracic radiotherapy
20 Enrolling by invitation Efficacy Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary Adenocarcinoma
Condition: Cancer
Interventions: Drug: TCM;   Drug: EGFR-TKI

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years